Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dasabuvir Sodium

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tracking a successful DLBCL assault in PhII, MorphoSys out to OK for MOR208
    Tracking a successful DLBCL assault in PhII, MorphoSys out to OK for MOR208

    14 Mar 2018

    // S. Owermohle PLATFORM

    https://platform.mi.spglobal.com/web/client?auth=inherit#news/article?id=43852931&cdid=A-43852931-11822

    S. Owermohle PLATFORM
    14 Mar 2018
    Share Share
    Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
    Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report

    06 Jan 2018

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/marketing/opdivo-repatha-and-lynparza-likely-among-china-s-2018-blockbuster-nods-report

    Angus Liu FIERCE PHARMA
    06 Jan 2018
    Share Share
    AbbVie's Q4 sales miss the mark as cancer, hep C meds lag
    AbbVie's Q4 sales miss the mark as cancer, hep C meds lag

    27 Jan 2017

    // Carly Helfand FIEREC PHARMA

    http://www.fiercepharma.com/pharma/abbvie-sees-top-line-miss-q4-thanks-to-lagging-cancer-hep-c-sales

    Carly Helfand FIEREC PHARMA
    27 Jan 2017
    Share Share
    Conitec Approves Incorporation by SUS of AbbVie's Drug for Chronic Hepatitis C
    Conitec Approves Incorporation by SUS of AbbVie's Drug for Chronic Hepatitis C

    05 Dec 2016

    // PR NEWSWIRE

    http://www.prnewswire.com/news-releases/conitec-aprova-incorporacao-pelo-sus-do-medicamento-da-abbvie-para-hepatite-c-cronica-604818136.html

    PR NEWSWIRE
    05 Dec 2016
    Share Share
    EU Health Regulator Warns Some Hep C Drugs Could Reactivate Hep B
    EU Health Regulator Warns Some Hep C Drugs Could Reactivate Hep B

    03 Dec 2016

    // VL Nathan REUTERS

    http://www.reuters.com/article/us-eu-hepatitis-idUSKBN13R1T7

    VL Nathan REUTERS
    03 Dec 2016
    Share Share
    AbbVie Receives FDA Approval Of Viekria XR For The Treatment of Genotype 1 Chronic Hepatitis C
    AbbVie Receives FDA Approval Of Viekria XR For The Treatment of Genotype 1 Chronic Hepatitis C

    22 Jul 2016

    // FDA

    https://www.pharmacompass.com/pdf/news/AbbVie-Receives-FDA-Approval-Of-Viekria-XR-For-The-Treatment-of-Genotype-1-Chronic-Hepatitis-C-1469863214.pdf

    FDA
    22 Jul 2016
    Share Share